Key facts
- Cambrian Bio’s last known valuation is $180.0M (Aug 2023).
- It has raised $204.1M across 1 recorded rounds; the latest was Later Stage VC ($23.8M) in Dec 2025.
- Notable investors include Alumni Ventures, FJ Labs, Gaingels, RA Capital Management, Capital Factory — 41 tracked in total.
- 1 investment vehicle was formed to buy Cambrian Bio shares in the last 12 months, reporting $820K sold to 43 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 41 names
- ·Watchlist + deal alerts for Cambrian Bio
Funding rounds
1 roundsSecondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Cambrian Bio shares, reporting $820K sold to 43 investors. Most recent filing Jun 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Cambrian Bio
Developer of a portfolio of medicines designed to target the causes of age-related diseases. The company develops therapies and medicines to create interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life, enabling scientists to transmit their discoveries from the lab into the clinic and bring medicines to patients in need.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 28
- Website
- cambrianbio.com/
- Ownership
- Privately Held (backing)
Cambrian Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cambrian Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cambrian Bio in its N-PORT filings yet. We sweep new filings monthly.